Tag: fund

WUHU, China, June 09, 2026 (GLOBE NEWSWIRE) -- The winners of the 47th Telly Awards were officially announced. Return of the Cheetah: Horn of Africa, a public welfare documentary co-produced by JETOUR and DISCOVERY Channel, received three major honors, including Gold Winner in General-Documentary: Short Form, Silver Winner in Craft-Videography & Cinematography, and Silver Winner in General-Nature & Wildlife. The film also won a Gold Tower Award at the New York Festivals Advertising Awards, earning international recognition for its outstanding production quality and commitment to wildlife conservation.

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS

ING rolls out global subscription banking model

DENVER, June 09, 2026 (GLOBE NEWSWIRE) -- Futurionex, a digital asset trading platform, today announced the completion of key enhancements to its client asset protection system. These improvements are part of the company’s preparations for its Markets in Crypto-Assets (MiCA) license application, which remains on track for submission in the third quarter of 2026.

HOUSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Devon Energy Corp. (NYSE: DVN) today provided an updated outlook for the combined company following the recent completion of its transformative merger with Coterra Energy. Supplemental guidance tables for the combined entity are included below and a presentation is available on the company’s website at www.devonenergy.com.

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).